Sponsor of the Day:
Jerkmate
https://www.oncologyeducation.com/oncology-career-hub/
Oncology Career Hub - OncologyEducation
career huboncology
https://www.oncologyeducation.com/about-us/improving-patient-care-through-oncology-education/
Improving Patient Care Through Oncology Education - OncologyEducation
improving patient careoncologyeducation
https://www.oncologyeducation.com/contact-us/
Contact Us - OncologyEducation
usoncologyeducation
https://www.oncologyeducation.com/my-account/
My account - OncologyEducation
accountoncologyeducation
https://www.oncologyeducation.com/other-topics/
Other Topics - OncologyEducation
topicsoncologyeducation
https://www.oncologyeducation.com/infographics/relativity-047-4-year-update-nivolumab-relatlimab-in-advanced-melanoma/
RELATIVITY-047 4-Year Update: Nivolumab + Relatlimab in Advanced Melanoma - OncologyEducation
Feb 4, 2026 - Explore 4-year data from RELATIVITY-047. 52% OS rate for NIVO + RELA in 1L advanced melanoma. Download the clinical infographic for Canadian specialists.
4 yearadvanced melanomarelativity047update
https://www.oncologyeducation.com/
Latest Resources for Oncology Professionals - OncologyEducation
latest resourcesoncology professionalsoncologyeducation
https://www.oncologyeducation.com/about-us/
About Us - OncologyEducation
usoncologyeducation
https://www.oncologyeducation.com/videos/management-of-msi-h-dmmr-metastatic-colorectal-cancer/
Management of MSI-H/dMMR Metastatic Colorectal Cancer - OncologyEducation
Dec 3, 2025 - test Studies/trials discussed: Abstract #3501 – Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) or NIVO monotherapy for microsatellite...
msi h dmmrmetastatic colorectal cancermanagementoncologyeducation